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Every year stroke claims more than 6 million lives worldwide. The majority of them are
ischemic stroke. Small molecule-based therapeutics for ischemic stroke has attracted
a lot of attention, but none has been shown to be clinically useful so far. Hypoxia-
inducible factor-1 (HIF-1) plays a crucial role in the transcriptional adaptation of cells to
hypoxia. Small molecule-based hypoxia-mimetic agents either stabilize HIF-1α via HIF-
prolyl hydroxylases (PHDs) inhibition or through other mechanisms. In both the cases,
these agents have been shown to confer ischemic neuroprotection in vitro and in vivo.
The agents which act via PHD inhibition are mainly classified into iron chelators, iron
competitors, and 2 oxoglutarate (2OG) analogs. This review discusses HIF structure
and key players in the HIF-1 degradation pathway as well as the genes, proteins
and chemical molecules that are connected to HIF-1 and how they affect cell survival
following ischemic injury. Furthermore, this review gives a summary of studies that used
PHD inhibitors and other HIF-1α stabilizers as hypoxia-mimetic agents for the treatment
of ischemic injury.
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INTRODUCTION
HIF-1 is a transcription factor that acts as a master regulator of O2 homeostasis (Semenza, 1998).
It modulates the expression of an array of genes (Figure 1), and many of them are involved in
the cellular adaptation to hypoxia (Semenza, 2001). Vascular endothelial growth factor (VEGF),
Erythropoietin (EPO), glucose transporter 1 (GLUT1), heme oxygenase 1 (HO-1), and endothelial
nitric oxide (eNOS) synthase are some of the genes that are directly involved in HIF-1 mediated
cellular response to hypoxia (Schoﬁeld and Ratcliﬀe, 2004). As HIF-1 stabilization is an endogenous
cellular mechanism to reduce hypoxia-induced injury, it is hypothesized that pre and post-hypoxic
stabilization of HIF-1 by external means can enhance protection (Shi, 2009). Among these foreign
interventions, the small molecule-based HIF-1 stabilization is widely studied and has shown
promising results (Siddiq et al., 2005). Most of the small-molecules used for this purpose either
mimic or compete with the co-factors or co-substrates of HIF-1 degradation pathway. The small
molecules that are used to stabilize HIF-1α are widely known as hypoxia-mimetic agents. Some
of the familiar hypoxia-mimetic agents are desferrioxamine (DFO) and cobalt chloride (CoCl2)
(Zeng et al., 2011). Apart from these small molecules, there are newly found mRNAs and other
compounds which stabilize HIF-1α. In this review, we discuss the small chemical molecules and
other biological compounds that have conferred protection against ischemic stroke injury viaHIF-1
pathway stabilization.
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HIF STRUCTURE AND PATHWAY
Hypoxia-inducible factor belongs to the PAS family (PER-ARNT-
SIM), and functionally active HIF consists of two basic helix-
loop-helix (bHLH) protein subunits, alpha and beta/ARNT (aryl
hydrocarbon receptor nuclear translocator). Apart from bHLH,
N-terminal half of HIFs composed of Per-ARNT-Sim (PAS)
homology domains. The bHLH and PAS regions are involved
in the heterodimerization and DNA binding, respectively. The
terminal-transactivation domains (TADs) are present in the
C-terminal region of HIF, and they control the transcriptional
activity of the protein (Figure 2) (Beaudry et al., 2016).
The alpha subunit of HIF has three isoforms, HIF-1α, HIF-2α,
and HIF-3α. Likewise, the beta subunit has three isoforms,
ARNT, ARNT2, and ARNT3 (Semenza, 2000). The HIF-1α/β
dimer controls the transcription of genes by binding to a core
DNA motif (G/ACGTG) in hypoxia-response elements (HREs).
The HIF-1β subunit is constitutively produced in the nucleus
whereas the stability of HIF-1α depends on the availability of
oxygen (Vadlapatla et al., 2013). Under hypoxic condition, HIF-
1α is stable and transported to the nucleus. However, under the
normoxic condition, HIF mediated transcription is inhibited by
the HIF prolyl hydroxylases (PHDs) and asparaginyl hydroxylase
(FIH). PHD2 hydroxylates the two proline residues (402 and
564) on the oxygen-dependent degradation domain (ODDD)
of HIF-1α and makes it susceptible to ubiquitin-mediated
proteolysis via von Hippel–Lindau tumour suppressor (pVHL)
binding. On the contrary, FIH hydroxylases asparagine residue
(803) of HIF-1α and prevents binding of the transcriptional co-
activators (p300/CBP) to HIF-1α (Figure 3) (Speer et al., 2013).
Hydroxylation of HIF α subunit by PHDs is an evolutionarily
conservedmechanism of sensing the oxygen concentration inside
the cell. Thus, stabilization of HIF-1α by an exogenous technique
may activate transcriptional and posttranscriptional responses
that will help the cell to overcome hypoxic damage (Masoud and
Li, 2015).
HIF-1α degradation can be restrained by inhibiting the activity
of PHDs and FIH. PHDs and FIH belong to a class of enzymes
known as 2-oxoglutarate dependent dioxygenases and are the
most prominent known family of non-heme oxidizing enzymes
(Schoﬁeld and Zhang, 1999). There are three PHD isoforms,
PHD1, PHD2 and PHD3. Even though these isoforms have a
similar C-terminal catalytic domain, N-terminal sequences diﬀer
signiﬁcantly (Siddiq et al., 2009). mRNA expression analysis
revealed that the expression patterns of PHD isoforms are tissue-
speciﬁc and all the isoforms play a unique role in the regulation
of HIF-1α and HIF-2α (Appelhoﬀ et al., 2004). Both PHDs and
FIH require oxygen, iron (Fe2+) and 2OG for the hydroxylation
reaction (Singh et al., 2012).
Hypoxic microenvironments are important in the developing
embryo, and they control cellular diﬀerentiation. These hypoxic
microenvironments prompt the cells to activate HIFs which
in turn regulate the development of the blood, vasculature,
placenta, nervous system, and other organs (Simon and Keith,
2008). Thus, HIFs have a crucial role in embryonic development
and survival. Validating the role of HIF during embryonic
development, studies using HIF-1α deﬁcient mouse embryos
stopped developing by day 9 and died by day 10.5 due to extensive
cell death and other abnormalities (Semenza, 2014).
THE RELEVANCE OF THE HIF-1
PATHWAY IN ISCHEMIC STROKE
Cerebral stroke is a signiﬁcant cause of morbidity and mortality
worldwide (Kim and Johnston, 2013). More than 80% of strokes
are ischemic while the remaining is hemorrhagic. Ischemic stroke
occurs when a vessel supplying blood to the brain is obstructed
due to a thrombus, embolus, or other blockage (Harten et al.,
2010). Prevention of neuronal death and improving the recovery
following ischemic injury are the central focuses of developing
stroke therapeutics. Apart from tissue plasminogen activator
(tPA), no drugs are able to confer neuroprotection following
ischemic stroke in clinical studies (Shi, 2009).
A large number of preclinical studies that used PHD
inhibitors were able to show that the activation of HIF-
1 can be a potentially attractive way to achieve signiﬁcant
neuroprotection following ischemic injury (Karuppagounder and
Ratan, 2012). Apart from stroke, PHD inhibition persistently
extended neuroprotection in diverse neurological disease models
(Speer et al., 2013). At the same time, a few studies observed
adverse eﬀects on brain cells upon treatment with PHD
inhibitors mostly because of the activation of pro-death
proteins like BNIP3 and NIX (Chen W. et al., 2009). As hypoxia
induces HIF-1α expression, most hypoxia-mimetic agents up-
regulate HIF-1α and orchestrate its downstream gene expression
(Karuppagounder and Ratan, 2012). Neuroprotection viaHIF-1α
stabilization following ischemic stroke is still a controversial topic
due to its link to a vast variety of genes that mediate both adaptive
and pathological processes (Vangeison et al., 2008). Unlike PHD
inhibitors, not many FIH inhibitors are discovered, and the
possibility of attaining neuroprotection via FIH inhibition has yet
to be fully explored.
The altered expression of HIF-1 and its downstream
genes during hypoxia have been very well studied in both
in vitro and in vivo models (Semenza, 2001). Several processes
like angiogenesis and erythropoiesis are connected to HIF-1
stabilization. Apart from this, recent studies were able to deduce
more novel phenomena and genes linked to the HIF-1 pathway
(Valsecchi et al., 2011; Liu et al., 2012). In a transient global
ischemia model, HIF-1 expression was enhanced as early as 1 h
in the recovery phase, and this enhanced expression lasted for
7 days (Chavez and Lamanna, 2002). Besides, expression of HIF-
1 regulated genes, EPO and GLUT1 were elevated during the
reperfusion period. The above study also found that insulin-like
growth factor-1 (IGF-1) was able to induce HIF-1 expression
in vitro and in vivo.
HIF-2α has 48% structural similarity with HIF-1α, and it
also activates HRE-dependent gene transcription (Hu et al.,
2003). However, HIF-1α andHIF-2α have discrete transcriptional
targets and perform non-redundant roles. Their expression
patterns are tissue speciﬁc and the part played by these
isoforms in tumor progression is contrasting (Ratcliﬀe, 2007).
A study observed that HIF-1 mediated genes conferred brain
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FIGURE 1 | Network showing HIF-1 connected to its target genes (adapted from: http://www.grnpedia.org/trrust/). Colors inside the shape represent the type of
interaction.
FIGURE 2 | Domain structure of human HIF subunits and isoforms.
hypoxia-induced tolerance rather than HIF-2 regulated genes
(Bernaudin et al., 2002). They came to this conclusion
as because HIF-2α levels did not increase signiﬁcantly in
neuronal cells following hypoxia. Further, this study showed that
adrenomedullin, propyl 4-hydroxylase α, metallothionein 1 (MT-
1), mitogen-activated protein kinase phosphatase 1(MKP-1),
CUGBP Elav-Like Family Member (CELF), 12-lipoxygenase and
carbonic anhydrase 1 (CAR-1) are regulated by hypoxia. HIF-1α
was also found to bind to the caspase-3 gene promoter region
speciﬁcally. Moreover, HIF-1α and procaspase-3 showed similar
expression pattern following photothrombotic cerebral ischemia
(Hoecke et al., 2007).
Hypoxia-inducible factor responsive genes perform a
signiﬁcant role in the ischemic preconditioning (IPC) induced
neuroprotection (Jones and Bergeron, 2001; Valsecchi et al.,
2011). Up-regulation of cytochrome P450 2C11 by HIF-1α has
a role in the tolerance induced by hypoxic preconditioning
(HPC) in astrocytes (Liu and Alkayed, 2005). 2-methoxyestradiol
(2ME2) is a metabolite of estrogen and an inhibitor of HIF-1α
(Zhou et al., 2008). A study by Zhou and co-workers showed that
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FIGURE 3 | Regulation of HIF-1 during hypoxia and normoxia.
2ME2 aggravated the CA1 hippocampal cell death after global
ischemia in rats (Zhou et al., 2008). Glucose at a concentration
of 25 mM up-regulated the expression of HIF-1α in rat primary
cortical neurons exposed to hypoxia. Surprisingly, the study
showed that along with hypoxia, a reducing environment
is required for the stabilization of HIF-1α in neuronal cells
(Guo et al., 2008). The above lab also found out that BCL2
interacting protein 3 (BNIP3) and BCL2 interacting protein
3 like (NIX/BNIP3L) play a role in the HIF-1α mediated
neuroprotection during ischemia-reperfusion (Guo, 2017).
Sodium-calcium exchanger-1 (NCX1) helps in the
maintenance of Na+ and Ca2+ homeostasis (Michel et al.,
2014). In a recent study, it was demonstrated that NCX1 gene
is controlled by HIF-1 and contributes to the HIF-1 mediated
neuroprotection during brain preconditioning (Valsecchi et al.,
2011). The mammalian target of rapamycin (mTOR) belongs to a
lipid kinases family, and it is involved in cell growth, survival, and
proliferation (Yoon, 2017). mTOR facilitated neuroprotection
under ischemic conditions through the activation of HIF-1α, and
by the regulation of VEGF expression and neuronal apoptosis in
developing rat brain (Chen et al., 2012).
A few studies showed that deletion of PHD2 in neuronal
cells has beneﬁcial eﬀects like improvement in histological
and functional outcomes and neovascularisation through the
promotion of HIF-VEGF axis (Li et al., 2016). Supporting
this observation, knockdown of HIF-1α before oxidative stress
aggravated the impairment of learning and memory in rat model
(Yang et al., 2017).
The eﬀect of HIF-1α stabilization is not much studied in
glial cells as in neurons. In a study by Vangeison et al. (2008)
explored the impact of knocking down HIF-1α speciﬁcally in
astrocytes in neuron/astrocyte co-cultures exposed to hypoxia.
Selective deletion of HIF-1α in astrocytes signiﬁcantly protected
neurons from hypoxia-induced neuronal death in co-cultures.
Myeloid-speciﬁc knockout (KO) of HIF-1α resulted in faster
behavioral recovery of mice subjected to MCAO (Bok et al.,
2017). The HIF-1α KO mice had fewer inﬁltrating microglia
and apoptotic neurons in the hippocampus following MCAO
compared to its wild-type counterpart. The above group also
observed that HIF-1α governs microglial phagocytosis and
production of ROS and TNF-α under ischemic conditions.
Sirtuin 1 (Sirt 1) has many vital roles in response to metabolic
stress, especially cerebral ischemia (Koronowski and Perez-
Pinzon, 2015). A study by Jablonska et al. (2016) observed that
the presence of HIF-1α plays an essential role in hypoxia-induced
Sirt1 expression in oligodendrocyte progenitor cell (OPC).
The Pro and Anti-apoptotic Face of
HIF-1α Stabilization in Ischemic Stroke
HIF-1 has both pro and anti-apoptotic features. It improved the
expression of genes like EPO and VEGF that are linked to several
pathways related to neuroprotection. However, it also participates
in the pro-apoptotic process by stabilizing the tumor suppressor
protein p53 during severe hypoxia (Fan et al., 2009). Further, it
promoted cell necrosis in collaboration with calcium and calpain.
It was found to increase blood-brain barrier (BBB) permeability
and thus heighten brain oedema.
In agreement with the pro-apoptotic role of HIF-1, a few
studies found that HIF-1deﬁciency can confer neuroprotection
against acute hypoxia-induced cell death in mice (Helton et al.,
2005). A similar trend was observed in a study by Chen C. et al.
(2009) that used HIF-1α siRNA. The authors showed that HIF-1α
siRNA treatment protected neurons from ischemic injury in vivo
through the inhibition of VEGF and apoptosis-related proteins
like p53 and Caspase-3 along with HIF-1α. The c-glycosylated
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ﬂavone, vitexin (5, 7, 4-trihydroxyﬂavone-8-glucoside) is a HIF-
1α inhibitor (Min et al., 2015). Inhibition of HIF-1α in the
early stages of neonatal cerebral ischemia with vitexin conferred
neuroprotection in vivo.
Further, Chen et al. (2008) observed that inhibition of HIF-1α
by 2ME2 5min after the hypoxia-ischemia protected the neuronal
cells in the neonatal rat. There was no signiﬁcant reduction in
infarct volume when the treatment with the 2ME2 was delayed
for 3hrs. HIF-1 inhibition also protected BBB and reduced brain
oedema. While, the treatment with HIF-1α stabilizer DMOG,
increased BBB permeability and brain oedema. Additionally,
Barteczek et al. (2016) showed that HIF-1 and HIF-2 are not
needed for cell survival under hypoxic conditions. This study
also showed that HIF-1/2 deﬁciency might protect neurons from
early neuronal cell death and neurological impairment caused by
ischemic stroke.
Additionally, Aminova et al. (2004) showed that the pro-
death or anti-death role of HIF-1α in a cell depends on the type
of death stimulus. HIF-1α overexpressing HT22 cells showed
increased sensitivity to glutamate toxicity, but they were more
resistant to cell death induced by camptothecin or tunicamycin
or thapsigargin. When the level of p53 is low, hypoxia-induced
HIF-1α triggers the transcriptional activation of adaptive genes.
However, during severe and sustained hypoxia, p53 levels
increase along with HIF-1α stabilization and these proteins
together activate pathological genes such as BAX (Halterman
et al., 1999).
Tricyclodecan-9-ylxanthogenate (D609) down-regulates HIF-
1α similar to 2ME2. Treatment with D609 or 2ME2 reduced
infarct volume and improved neuroscore in rats following
MCAO (Chen et al., 2007). These HIF-1α inhibitors decreased
the expression of VEGF, BNIP3 and cleaved caspase 3. According
to a study carried out by Mayhan (1999), VEGF promoted
the BBB permeability via a nitric oxide synthase/cGMP-
dependent pathway. Since VEGF is directly controlled by
HIF-1, the negative eﬀect of HIF-1α in ischemic stroke may
be linked to VEGF. Information from the above studies
suggests that the positive or negative eﬀects of HIF-1 depend
on cell type and the severity of hypoxia. The nature of
ischemic insult also plays a role in determining whether HIF-
1α will advocate pro-death or pro-survival pathways (Shi,
2009).
Biphasic Expression Pattern of HIF-1α
Following Ischemic Injury
Biphasic expression pattern of HIF-1α was observed in some
of the studies following in vitro and in vivo models of cerebral
ischemia. A study by Liu et al. (2015) monitored the changes
in the HIF-1α gene and protein expression at diﬀerent time
points in amiddle cerebral artery occlusion (MCAO)model using
an embolus (eMCAO). HIF-1α mRNA level gradually increased
following ischemia and peaked at 6 h. After that, it slowly
decreased and came to a low level at 24 h. A similar pattern of
expression was observed from 24 to 168 h reaching the peak at
72 h. An exactly same trendwas seen in the case of HIF-1α protein
expression.
According to a study by Yeh et al. (2010), inhibition of HIF-
1α in the early time point (0.5 h after ischemic stress) abated
brain injury and oedema. While inhibiting HIF-1α at a later
stage (8 h after ischemic injury) increased brain damage and
decreased VEGF expression. Theoretically, HIF-1α induction at
the early time points of ischemia activates apoptotic pathways,
and at late time points, it promotes cell survival pathways.
Comparable expression pattern of HIF-1α was observed in other
study carried out by Baranova et al. (2007) in the MCAO
model.
In neonatal rat brain, uponMCAO,HIF-1α protein expression
was elevated immediately (0 h, without reperfusion) and peaked
at 8 h, and then deteriorated at 24 h after reperfusion (Mu
et al., 2003). VEGF protein expression was also similar to
that of HIF-1α. This variation shows the biphasic nature of
HIF-1 expression following cerebral ischemia in neonatal brain.
When compared to the expression pattern in neuronal cells,
similar alterations in expression of HIF-1α mRNA and protein
were observed in microglia cells following exposure to hypoxic
conditions (Wang et al., 2017). These studies have enhanced
our understanding of the dual and contrasting roles of HIF-1α
expression in neurons following ischemic stroke. To a certain
extent, this biphasic expression pattern of HIF-1α will decide
the time window of administration of drugs that act via HIF-1α
stabilization for maximum protection.
HYPOXIA MIMETIC AGENTS IN
ISCHEMIC STROKE
The term “hypoxia mimetic agent” has been widely used to
indicate biological or chemical molecules which are used to
up-regulate HIF-1α expression. They do it either via PHDs
inhibition or some other mechanisms. Here, in this review, HIF-
1α stabilizers are broadly classiﬁed according to the involvement
of PHDs in the stabilization process.
HIF-1α Up-Regulation via Inhibition of
PHD Pathway
Most of the HIF-1α up-regulators act via PHD inhibition.
Currently, the following interventions are used stabilize HIF-1α
and mimic hypoxic conditions via PHD inhibition: (a) reduce
Fe2+ availability using iron chelators; (b) introduce metal ions
that will compete with Fe2+; (c) use 2OG analogs. HIF-1α
stabilizers that do not come under any of the above categories
are discussed under a separate subheading.
Iron Chelators and Competitors
Iron chelators are small molecules that bind very tightly to iron
and reduce the amount of free divalent iron available for PHD
mediated HIF hydroxylation reaction (Peyssonnaux et al., 2008).
Deferoxamine mesylate (DFO) is a widely used iron chelator
that removes excess iron from the body (Fisher et al., 2013).
Previously, it was thought that iron chelators prevent oxidative
injury by obstructing hydroxyl radical formation but later studies
revealed that iron chelators inhibit the action of PHDs and
upregulate HIF-1 expression (Siddiq et al., 2005). Alternatively,
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iron competitors (mostly divalent metal ions) that compete with
Fe2+ in the PHD mediated HIF-1 hydroxylation process can be
used. Although there are several iron competitors like Ni2+ and
Mn2+, Co2+ in the form of cobalt chloride (CoCl2) is the most
widely used iron competitor for PHD inhibition (Fandrey et al.,
2006). A recent study by Na et al. (2015) reported that Zn2+ could
selectively inhibit PHD3 over PHD2.
A study by Zaman et al. (1999) was one of the ﬁrst studies
to explore HIF-1 mediated neuroprotection by iron chelators
following hypoxic stress. In this study, iron chelators, DFO and
mimosine (MIM) protected embryonic cortical neurons from
glutathione depletion and oxidative stress-induced cell death
at a concentration of 100 µM. Neuroprotective capabilities
of these agents were also comparable to their ability to
augment DNA binding of HIF-1. These compounds also up-
regulated mRNA and protein expression of HIF-1 controlled
genes. Likewise, cell death induced by depletion of glutathione
was decreased signiﬁcantly by treatment with CoCl2 at a
concentration > 200 µM, a competitive inhibitor of iron. CoCl2
also elevated the HIF-1α protein expression.
Subsequently, several studies explored the ability of iron
chelators for HIF-1 mediated neuroprotection against hypoxic
injury. Siddiq et al. (2005) investigated the mechanism by which
DFO oﬀered protection in neuronal cells. In cortical neurons,
HIF-1α was stabilized upon treatment with 100 µM DFO and
protected cells from oxidative glutamate toxicity. Similarly, Prass
et al. (2002) demonstrated the neuroprotective eﬀect of DFO
against OGD injury in puriﬁed cortical neurons. DFO at a
concentration of 150 µM/L induced 47% reduction in cell death
in primary cortical neurons subjected to OGD.
Compound A is a novel proprietary (Fibrogen Inc.,
United States) small molecule iron chelator. It stabilized
HIF-1α in cortical neurons and increased the expression of
HIF-1 targeted genes at a concentration of 40 µM (Siddiq et al.,
2005). It also conferred protection against oxidative glutamate
toxicity. In addition to its protective eﬀect in in vitro studies,
treatment with 100mg/kg of compound A, stabilized HIF-1 in rat
brain within 3h. It also reduced infarct volume by 67%, compared
to control littermates. In hippocampal neurons from newborn
mice, pretreatment with 10 mM/L DFO decreased OGD induced
cell death by 45% compared to the control group. The protection
conferred by DFO diminished upon cell’s transfection with
anti-HIF-1α. This ﬁnding suggests that the protection by DFO is
through HIF-1α induction (Hamrick et al., 2005).
Prolyl hydroxylases isoforms diﬀer in their expression
patterns, tissue distribution, subcellular localization, and their
ability to hydroxylate HIF-1α (Siddiq et al., 2009). Based on
these characteristics, Siddiq and co-workers hypothesized that
the neuroprotection conferred by PHD inhibitors are PHD
isoform-speciﬁc and independent of HIF-1. In this regard,
they investigated the role of PHD and HIF isoforms in
giving neuroprotection against normoxic oxidative death by the
treatment of PHD inhibitors in primary rat neurons. When
compared to a previous in vitro study carried out by Zaman
et al. (1999), they observed something distinctive in this study.
They noted that the prevention of normoxic oxidative neuronal
death by DFO is through the inhibition of PHD1 and HIF-1α
doesn’t have any role in this mechanism. They also noted that
its HIF-2α, not HIF-1α controls the sensitivity to normoxic
oxidative neuronal death.
In comparison to adult CNS, the neonatal brain is highly
sensitive to the availability of essential substrates. Treatment
with 60 mg/kg of CoCl2 and 200 mg/kg of DFO increased the
level of HIF-1α protein in rat pups compared to the vehicle-
injected controls (Bergeron et al., 2000). Compared with that
in vehicle-injected controls, preconditioning with DFO and
CoCl2 24h before hypoxia-ischemia gave 56 and 75% protection,
respectively.
Desferrioxamine promoted the binding of HIF-1 to DNA and
transcription of EPO in vivo. There was a 20-fold increase in
DNA binding of HIF-1 upon DFO application. The tolerance
induced by DFO was time and dosage-dependent (Prass et al.,
2002). Expression of GLUT1 protein was elevated in rat brain
by the treatment of 300 mg/kg of DFO. Brain lesion area
and whole brain cell loss reduced upon treatment with DFO.
Notably, DFO treatment didn’t aﬀect striatal lesion but provided
a 20% reduction in cortical injury compared with the vehicle
group. Likewise, there was a 62% decrease in thalamic shrinkage
by the treatment of DFO in comparison with vehicle-treated
animals. Neurological score and sensorimotor performances also
improved upon treatment with DFO (Freret et al., 2006).
Deferasirox (DFR) is an orally administrated iron chelator and
is in clinical use with high tolerance (Hatcher et al., 2009). As
previously observed in the study by Siddiq et al. (2009); Zhao
and Rempe (2011) also showed that neuroprotection conferred
by DFO and DFR following MCAO does not require HIF-1α in
mice. They also observed that both DFO and DFR do not induce
expression of HIF-1 target genes.
2, 2′-dipyridyl (DP) is a liposoluble iron chelator, and it is
used to regulate HIF-1α expression up. Experiments show that
DP treatment reduced infarct volume and maximal infarct area
and thus signiﬁcantly decreased histological damage (Demougeot
et al., 2004). There was a 42% reduction of infarct volume and
a 25% decrease in the maximal infarct area upon treatment with
DP. It protected both endothelial cells and neurons from ischemic
injury. Besides, DP treatment in rats reduced ischemia-induced
reactive oxygen species (ROS) production and suppressed the
transformation of penumbra into infarct.
In chemical photothrombosis stroke models, DP treatment
hindered the progression of infarct core and the surrounding
regions (Hoecke et al., 2005). The density of apoptotic
bodies reduced upon treatment with DP in both infarct
core and surrounding pale region. Compared to the vehicle-
treated animals, DP treatment decreased and limited the DNA
fragmentation only to P1 region. Upon treatment with DP, there
was a signiﬁcant reduction in procaspase-9 cleavage in the P1
and P2 regions. Similarly, procaspase-3 cleavage was decreased
in these regions. There was also a drop in cleaved caspase-3 in the
entire infarct region upon treatment with DP in vivo.
Neuroprotection achieved by DP post-treatment was lower
when compared with DP pretreatment (Baranova et al.,
2007). Further, the protective eﬀect produced through the
administration of DP before or after MCAO was signiﬁcantly
attenuated but not completely abolished in neuron-speciﬁc
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HIF-1α-deﬁcient mice. This shows the involvement of an
alternative mechanism in giving neuroprotection upon DP
treatment. Similarly, another study (Jones and Bergeron,
2001) observed that there was no change in expression of
genes modulated by HIF-1 upon preconditioning with CoCl2
suggesting a surrogate process may be involved in the induction
of tolerance by CoCl2 in the brain of newborn rats.
2OG Analogs
Numerous hydroxybenzenes, hydroxybenzoic acids and
analogous compounds have similar structural features as both
2-oxoglutarate and ascorbate. They can compete with these
molecules and inhibit prolyl 4-hydroxylase enzymes (Majamaa
et al., 1986). 10 µM dihydroxybenzoic acid (DHB) stabilized
HIF-1α and increased the transcription of HIF-1 dependent
genes. DHB conferred protection to cortical neurons exposed to
oxidative glutamate toxicity (Siddiq et al., 2005).
N-oxalylglycine can inhibit most of the 2OG-dependent
oxygenases and other enzymes (Al-Qahtani et al., 2015).
Dimethyloxalylglycine (DMOG) is a readily cell permeable ester
of N-oxalylglycine. DMOG has a similar structure to 2OG. It
competes with PHD co-substrate, 2OG and prevents HIF-1α
degradation (Siddiq et al., 2009; Nagel et al., 2011). Twenty four
hour treatment with DMOG increased the protein expression of
HIF-1α and mRNA levels of VEGF in cortical neurons growing
under normoxic condition. Preconditioning with DMOG for
24 h before OGD signiﬁcantly reduced OGD-induced cell death
in cortical neuron cell. Similarly, post-treatment with DMOG
also reduced cell death. This protection abrogated by the
pretreatment of HIF-1α-shRNA showed the need of HIF-1α for
achieving neuroprotection using PHD inhibitors (Ogle et al.,
2012).
In vivo stabilization of HIF-1 was observed within 6 h of
administration of DHB. There was a signiﬁcant reduction of
infarct volume uponDHB treatment compared to control (Siddiq
et al., 2005). Studies in mice showed that intraperitoneal injection
of DMOG increased the level of HIF-1α protein up to threefold
in a time-dependent manner in mouse brain cortex. It also
elevated the expression of HIF-1 controlled genes that regulate
erythropoietin and pyruvate dehydrogenase kinase-1. Further,
post-OGD treatment with DMOG reduced the infarct volume
in an animal stroke model. In addition to this, it stimulated
pro-apoptotic caspase-3 protein, curtailed behavioral deﬁcits and
decreased the loss of local blood ﬂow in themiddle cerebral artery
territory. These attributes nulliﬁed upon inhibition of HIF-1α by
Digoxin (Ogle et al., 2012).
In another study by Nagel et al. (2011), DMOG reduced
ischemic injury and improved behavior and neuroscore after
both permanent and transient MCAO in adult male Wistar rats.
Regional cerebral blood ﬂow also improved. There was also
a reduction in the amount of BBB breakdown. A consistent
increase in the expression of both mRNA and protein levels
of VEGF and endothelial nitric oxide synthase observed after
DMOG treatment. As seen in the case of DFO, a study by Siddiq
and co-workers suggested that the neuroprotection exerted by
DMOG and DHF does not require HIF-1α stabilization and
instead inhibit the PHD1 isoform (Siddiq et al., 2005).
PHD Inhibitors With an Alternative Mechanism of
Action
This section also includes HIF-1α stabilizers, but their exact
mechanism of PHD inhibition is not either mentioned in the
source paper or diﬀerent from the above classiﬁcation. These
molecules may act by binding directly to the active site of the
PHDs without mimicking 2OG or chelating the iron atom.
A study (Reischl et al., 2014) focusing on reducing neuronal death
following ischemic stroke via maintaining BBB integrity used a
novel PHD inhibitor, FG-4497. HIF-1α stabilized upon treatment
with FG-4497 in both primary murine astrocytes and the murine
cerebrovascular endothelial cell line. FG-4497’s capability to
inhibit HIF-1α proteolysis was higher than DMOG. It also
up-regulated the transcription of HIF-1 targeted genes VEGF
and EPO. In mouse hippocampal culture, FG-4497 signiﬁcantly
enhanced the survival of cells following OGD.
Intraperitoneal injection of FG-4497 elevated the amount
of HIF-1α in cerebral tissue and signiﬁcantly reduced infarct
size compared to vehicle-treated mice (Reischl et al., 2014).
FG-4497 pre-treatment reduces infarct volume in transient
MCAO models. Post-treatment with FG-4497 also showed
neuroprotection following permanent cerebral ischemia.
2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetic
acid (IOX3) is a novel inhibitor of PHDs (Chen et al., 2014). It has
a structure similar to FG2216, which promoted the expression
of EPO in vivo. Administration of IOX3 24h before a MCAO
TABLE 1 | Details about the studies that used non-PHD HIF-1α stabilizers as hypoxia-mimetic agents.
Sl. No. Study Compound(s) Type of compound Time of
administration
Stroke
model(s)
Cell/animal type
1 Liu et al., 2015 miR-335 microRNA Immediately or 24 h
after MCAO
eMCAO Male Wistar rats
2 Li et al., 2008 Isoflurane Anesthetic 24 h before OGD OGD Hippocampal neurons
3 Li et al., 2012 Isoflurane Not specified
(post-OGD/MCAO)
OGD/MCAO Male Sprague–Dawley rats;
Primary cortical neurons
4 Zhang Z. et al., 2014 NAC Antioxidant 30 min before MCAO MCAO Male Sprague–Dawley rats
5 Badawi and Shi, 2017 MG-132;
Epoxomicin
Proteasome inhibitor 24 h before MCAO OGD/MCAO C57/BL/6 male mice;
Primary cortical neurons
6 Doeppner et al., 2012 BSc2118 Proteasome inhibitor 12 h before MCAO MCAO Male C57BL/6N mice
7 Ratan et al., 2008 Tilorone Antiviral agent 24 h before MCAO MCAO Male Sprague–Dawley rats
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TABLE 2 | Details about the studies that used PHD inhibitors as hypoxia-mimetic agents.
Sl. No. Study Compound(s) Type of compound Time of administration Stroke model(s) Cell/animal type
1 Zaman et al., 1999 DFO Iron chelator Immediately or up to 10 h after HCA∗
treatment
Glutathione depletion model Rat primary neurons
Mimosine Iron chelator
CoCl2 Iron competitor
2 Siddiq et al., 2005 DFO 6 h before MCAO Glutamate-mediated
excitotoxicity/MCAO
Rat primary neurons; Adult male
Sprague–Dawley rats
DHB 2OG analog
Compound A Iron chelator
3 Bergeron et al., 2000 DFO 24 h before ligation Unilateral carotid artery ligation Male and female Sprague–Dawley rats
CoCl2
4 Prass et al., 2002 DFO 48 or 72 h before OGD/MCAO OGD/MCAO Rat primary neurons; Male Wistar rats
5 Freret et al., 2006 DFO Before and/or shortly after MCAO MCAO Sprague–Dawley rats
6 Baranova et al., 2007 DFO 6 h before or after MCAO MCAO Transgenic C57BL6/J male mice
DHB
DP Iron chelator
7 Siddiq et al., 2009 DFO Before or along with HCA Glutathione depletion model HT22 murine hippocampal cells
DHB
DMOG 2OG analog
8 Hamrick et al., 2005 DFO 1 h before and during OGD OGD Hippocampal cells
9 Mu et al., 2005 DFO Immediately after MCAO MCAO Female Sprague–Dawley rats
10 Hanson et al., 2009 DFO Multiple times before or after MCAO MCAO Male Sprague–Dawley rats
11 Zhao and Rempe, 2011 DFO Every day up to 4 weeks before MCAO MCAO Mice
DFR Iron chelator
12 Jones and Bergeron, 2001 CoCl2 24 h before MCAO MCAO Male and female Sprague–Dawley rats
13 Demougeot et al., 2004 DP Iron chelator 15 min before and 1 h after occlusion Cortical photothrombotic vascular
occlusion
Adult male Wistar rats
14 Hoecke et al., 2005 DP 15 min before and 1 h after occlusion Cortical photothrombotic vascular
occlusion
Adult male Wistar rats
15 Ogle et al., 2012 DMOG 24 h before OGD and 2 h after initiation
of OGD; 30 or 60 min after reperfusion
OGD/MCAO Primary neurons; Adult male
B6129PF2/J mice
16 Nagel et al., 2011 DMOG Multiple times before and one time after
MCAO
Permanent or transient MCAO Adult male Wistar rats
17 Reischl et al., 2014 FG-4497 Not specified 6, 24, and 48 h during OGD; 6 h before
or soon after MCAO
MCAO Primary murine astrocytes and HT-22
hippocampal neuronal cells; Male
C57BL/6 mice
18 Chen et al., 2014 IOX3 Not specified One day or immediately before MCAO MCAO Male C57/B6 mice
19 Zhou et al., 2017 GSK360A Not specified 18 and 5 h before MCAO MCAO Male Sprague–Dawley rats
20 Kontani et al., 2013 TM6008 Not specified Immediately after hypoxia Anaerobic chamber SHSY-5Y cells
21 Zhang Q. et al., 2014 HLJDT Unknown 24 h before OGD or MCAO OGD; MCAO Rat primary neurons; Male
Sprague–Dawley rats
∗HCA, homocysteic acid.
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improved neuroscores and reduced infarct volume in mice. It
also elevated the level of HIF-1α protein and EPO expression.
However, injection of IOX3 soon before the MCAO showed no
signiﬁcant neuroprotection. IOX3 also prevented BBB disruption
when treated 24 h before MCAO.
GSK360A is an orally active PHD inhibitor that has reduced
myocardial infarct size in the rat and murine heart (Ong
et al., 2014). Treatment with GSK360A increased the plasma
EPO and VEGF mRNA and protein levels (Zhou et al., 2017).
When compared to the vehicle-treated group, pretreatment
with GSK360A reduced post-stroke surgery neurological deﬁcits,
cognitive dysfunction and infarct volume 4 weeks after MCAO.
Another novel PHD inhibitor, TM6008 decreased cell death and
up-regulated HIF-1α levels in vitro. It also induced the protein
expression of HIF-1 downstream genes, HO-1, EPO, and glucose
transporter 3 (GLUT3) (Kontani et al., 2013).
Lately, molecular docking and simulation studies carried out
in our lab found folic acid (FA) to be an ideal compound that
binds to PHD2, FIH and pVHL alike at their HIF-1α binding
region (Davis et al., 2018). In vitro experiments showed that post-
ischemic treatment with FA up-regulated HIF-1 expression and
its downstream genes. Further, FA conferred neuroprotection
following OGD and promoted angiogenesis.
HIF-1α Up-Regulation Without the
Inhibition of PHDs
Non-PHD HIF-1α stabilizers relay on a mechanism other
than the classical PHD-HIF pathway to up-regulates HIF-1α.
Compared to the conventional PHD inhibitors, these molecules
are newly discovered. HIF-1α stabilization through IPC is not
discussed in this review as it is out of the scope of the title
theme.
A study by Liu et al. (2015) showed that miR-335 is a direct
regulator of HIF-1α, and has shown an inverse expression proﬁle
both in vivo and in vitro ischemic models. Treatment with miR-
335 decreased infarct volume immediately after MCAO, and
miR-335 inhibitor was found to be beneﬁcial at 24 h after MCAO
in a rat model. Thus, regulation of HIF-1α expression by miR-
335 at various time points manipulated the genes required for
adaption to hypoxia and ultimately resulted in the reduction of
infarct volume.
Preconditioning with 1.5% isoﬂurane protected neurons from
oxygen-glucose deprivation (OGD) injury by the induction of
HIF-1α protein, and this activation is linked to the Erk1/2
pathway (Li et al., 2008). Further, a recent study by the above
group showed the neuroprotection provided by isoﬂurane post-
conditioning via HIF-1α stabilization (Li et al., 2012). Post-
ischemic treatment with isoﬂurane reduced the infarct volume
and improved neurological scores. Both post and pre-ischemic
treatment with isoﬂurane treatment up-regulated iNOS mRNA
level.
N-acetylcysteine (NAC) has various therapeutic properties,
and it is an antioxidant (Dhouib et al., 2016). It is also protected
the brain from ischemic injury in preclinical studies (Zhang Z.
et al., 2014). A study by Zhang and colleagues observed that
pretreatment with 150 mg/kg of NAC increased the protein levels
of HIF-1α, EPO and GLUT3 in the ipsilateral hemispheres of
rodents. The group also found out that HIF-1 is responsible
for NAC mediated neuroprotection following MCAO. NAC
treatment up-regulated heat shock protein 90 (Hsp90) expression
and in turn interaction of Hsp90 to HIF-1.
A study by Badawi and Shi (2017) reported that 20S and 26S
proteasomal pathways were involved in HIF-1α degradation in
ischemic neurons. For the in vitro studies, MG-132, a proteasome
inhibitor was used and it stabilized HIF-1α protein better
than DMOG. A combination of MG-132 and DMOG had a
better eﬀect on HIF-1α stabilization than them individually.
Further, they observed that treatment with epoxomicin, another
proteasome inhibitor reduced infarct size and brain oedema
following oxidative stress in vivo by the stabilization of HIF-
1α. In vivo also a combination of epoxomicin and DMOG
yielded better protection. The study also showed that proteasome
inhibitors are more eﬀective than PHD inhibitors in providing
HIF-1α stabilization and neuroprotection.
Doeppner et al. (2012) tested a novel proteasome inhibitor
BSc2118 for its neuroprotective activity following ischemic
stroke. 12h pre-ischemic injection of BSc2118 conferred
signiﬁcant reduction of infarct volumes on day four. BSc2118
yielded long-term neuroprotection for as long as 3 months
with the post-stroke treatment. Apart from reducing the infarct
volume, BSc2118 was able to decrease brain oedema, and
BBB break down. Further, it promoted both angiogenesis and
neurogenesis. Using the knock out studies, they concluded that
all these positive eﬀects of BSc2118 were mediated by HIF-1α.
Tilorone is a lowmolecular weight antiviral agent (Ekins et al.,
2017). In a study by Ratan et al. (2008) tilorone at a concentration
of 100 mg/kg increased the stabilization of HIF-1α and elevated
the expression of its downstream genes in vitro. The stabilization
of HIF-1α by tilorone was independent of iron chelation and
HIF-PHD inhibition in vitro. Tilorone also signiﬁcantly reduced
infarct volume in vivo following MCAO.
Huang-Lian-Jie-Du-Tang (HLJDT) is a traditional Chinese
medicine with properties like heat-clearing and detoxiﬁcation
(Zhang Q. et al., 2014). In cerebral cortical neurons, pretreatment
with HLJDT increased HIF-1α, EPO and VEGF levels and
protected the cells against OGD. It decreased ischemia-induced
apoptosis and promoted proliferation in neuronal cells. HLJDT
also signiﬁcantly reduced cerebral infarction; cerebral water
content and improved neurological deﬁcient score in MCAO rat
models. All the hypoxia mimetic agents discussed in this review
either act by inhibiting PHDs or other mechanisms and they
ultimately regulate the expression of HIF-1. Tables 1, 2 gives
a summary of the studies that used hypoxia-mimetic agents to
obtain neuroprotection following ischemic injury.
CONCLUSION
Hypoxia causes the cell to accumulate HIF-1 in the nucleus
and up-regulate speciﬁc HIF-1 targeted genes so that cells can
overcome the adverse condition. All the hypoxia mimetic agents
are designed to act in such a way to boost this endogenous
mechanism. One way to do this is through the inhibition of
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PHDs. These PHD inhibitors come under either the iron chelator
and competitive inhibitor category or the 2OG analog category.
Other molecules rely on mechanisms other than PHD inhibition
to stabilize HIF-1α. Apart from a few newly discoveredmolecules,
widely used hypoxia-mimetic agents are DFO, DHB, CoCl2,
DP, and DMOG. These agents up-regulated HIF-1α levels and
regulated its downstream genes.
Further, these agents conferred signiﬁcant neuroprotection
both in vitro and in vivo experiments. As the progression
of ischemic brain injury is multifactorial, each of the HIF-1
regulated genes inﬂuences various cellular processes of infarct
advancement at diﬀerent time points. In most of the cases,
treatment with hypoxia-mimetic agents several hours before
or after the induction of hypoxia bestowed greater protection
compared to treatment with these agents soon before or after
oxidative stress. The neuroprotection conferred by these agents
also depends on the cell type and magnitude of the ischemic
injury.
However, there are studies which did not show
neuroprotection viaHIF-1 up-regulation and even demonstrated
its pro-death features. Therefore, the extent of neuroprotection
provided by HIF-1 in the case of ischemic injury is still a
debatable topic. Nevertheless, in light of studies discussed in
this review (Tables 1, 2); we can conclude that HIF-1’s beneﬁcial
characteristics appear to outweigh its adverse eﬀects. Many of the
harmful eﬀects of HIF-1α can be eliminated by carefully choosing
the time of administration of HIF-1α stabilizers. Type of hypoxia
mimetic agent used, nature of ischemic injury and kind of cell
targeted by the treatment are the other factors which aﬀect the
neuroprotection bestowed by HIF-1α stabilizers.
One drawback of using the conventional mimetic agent is that
several other enzymes use Fe2+ and 2OG as co-factor or co-
substrate. Therefore the use of iron chelators, competitive iron
inhibitors and 2OG analogs can create undesired interference
of diﬀerent pathways. In this regard, the introductions of novel
drugs that can speciﬁcally inhibit PHDs or stabilize HIF-1α
through other mechanisms need more consideration. Speciﬁcity
of PHD inhibitors can be achieved by the development of
molecules that can bind to the active sites in PHDs. These
agents could be analogous to the parts of HIF-1α that interact
with PHDs. The possibility of stabilizing HIF-1α via FIH
inhibition has not received much attention and warrants further
exploration.
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